Experimental Medicine Training Initiative
  log in
  log in
Cambridge University
Cambridge University

 

Renal Drug Discovery and Development

30/05/2019 to 30/05/2019


map of conference rooms https://www.downing-conferences-cambridge.co.uk/assembly-room

Programme

Day 1 | Thursday 30 May 2019


Time Item
09:00 to 09:30 Registration and Refreshments
Drawing Room, Howard Building
09:30 to 09:35 Welcome
Dr Vik Selvarajah (Clinical Lecturer) and Dr Joseph Cheriyan (Consultant Clinical Pharmacologist & EMI Training Lead), Division of Experimental Medicine & Immunotherapeutics
09:35 to 10:05 Overview of Drug Development in Chronic Kidney Disease (CKD)
Dr Rona Smith, Clinical Lecturer, University of Cambridge & Honorary NHS Consultant, Nephrology Cambridge University Hospitals Trust.
10:05 to 10:35 Phase 3 trials- reasons for lack of success (via Video TC)
Dr Phil Ambery, Global Clinical Leader, Diabetes, AstraZeneca AB, Gothenburg
10:35 to 11:05 Pre-clinical development - Challenges in predicting human dose-response for CKD treatments
Dr Christine Ahlström, Modelling & Simulation team leader, Gothenburg, AstraZeneca
11:05 to 11:20 BREAK
11:20 to 11:50 Recent developments in whole exome sequencing in CKD & potential for future target identification in CKD
Dr Slavé Petrovski Vice-president and Head of Genome Analytics, AstraZeneca Centre for Genomics Research (CGR), Cambridge
11:50 to 12:20 Research and advances on the treatment of Hyperkalemia
Dr Carol Moreno Senior Global Medical Affairs Lead, Astrazeneca Dr Toby Humphrey Clinical research fellow, department of medicine, University of Cambridge
12:20 to 13:30 LUNCH
13:30 to 14:00 Identifying therapeutic targets in immune-mediated kidney disease
Dr Menna Clatworthy Reader in Immunity and Inflammation, Department of Medicine, University of Cambridge, UK; Honorary Consultant Nephrologist, Cambridge University NHS Foundation Trust
14:00 to 14:30 T cell involvement in diabetic nephropathy & proteinuric renal disease: Abatacept (CTLA4-Ig) as a case study
Dr Lutz Jermutus, Senior Director, R&D, Product Development Team Leader Cardiovascular, Renal and Metabolism iMED, BioPharmaceuticals R&D, AstraZeneca. Industrial Fellow & Graduate Mentor Trinity Hall, University of Cambridge.
14:30 to 15:10 Break out groups CTLA-4: Re-purposing in CKD
Dr Victoria Parker, Director of Clinical Development in CVRM (CV, renal and metabolism), AstraZeneca & Honorary consultant endocrinologist, Cambridge University Hospitals Trust
15:10 to 15:30 BREAK
15:30 to 16:00 Kidney organ culture models for studying human disease
Professor John Bradley, Consultant Renal Physician and National Institute for Health Research Cambridge Biomedical Research Centre, and Director of Research for Cambridge University Health Partners
16:00 to 16:30 Belimumab – A phase 2 clinical trial in Renal Transplantation
Dr Shaun Flint, Early Development Leader at GlaxoSmithKline and a physician with nephrology and vasculitis experience
16:30 to 17:00 Clinical Trials in Nephrology - Challenges and Opportunities
Dr Thomas Hiemstra, Honorary consultant nephrologist, Cambridge University Hospitals Trust & trials methodologist, Cambridge Clinical Trials Unit
17:00 to 17:15 Conclusion
17:15 to 19:00 Networking with refreshments
19:00 to 22:30 Dinner

 

Meeting Details

  Venue
Downing College, Regent Street, Cambridge, CB2 1DQ

  CPD Points
6

 Book Now!

 

Forthcoming Meetings

Cancer Drug Discovery and Development

05/03/2019 to 05/03/2019

To understand cancer drug discovery and development through a range of lectures, panel discussions and case studies....

 

Renal Drug Discovery and Development

30/05/2019 to 30/05/2019

map of conference rooms https://www.downing-conferences-cambridge.co.uk/assembly-room ...

 

 

 

Copyright ©2019 Experimental Medicine Training Initiative - Cambridge University Hospitals. All rights reserved.